Dasatinib, Nilotinib and Standard-Dose Imatinib for the First-Line Treatment of Chronic Myeloid Leukaemia (TA251)

Technology Appraisal Guidance No. 251

Source: National Institute for Health and Care Excellence

This guidance should be read in conjunction with the following NICE guidance: NICE Technology Appraisal Guidance 70 (TA70) 'Guidance on the use of imatinib for chronic myeloid leukaemia'.

This guidance partially updates NICE Technology Appraisal Guidance 70 (published October 2003).

1. Guidance

1.1  Standard-dose imatinib1 is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).

1.2  Nilotinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme.

1.3  Dasatinib is not recommended for the first-line treatment of chronic phase Philadelphia-chromosome-positive CML.

1.4  People currently receiving dasatinib that is not recommended according to 1.3 should be able to continue treatment until they and their clinician consider it appropriate to stop.

1 The summary of product characteristics (SPC) for imatinib states that the recommended dosage of imatinib is 400 mg per day for patients in chronic phase CML.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA251

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:nice@nice.org.uk

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70)
Issue Date: April 2012


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in